WideCells Group PLC Investor Evening 12th July at Shard Capital.

WideCells Group PLC LON:WDC the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, has confirmed details of its upcoming Private Investor Event, to be held at 5.30pm on Wednesday 12 July 2017 at Shard Capital, 23(rd) floor, 20 Fenchurch St, London EC3M 3BY. With revenues now being received and set to increase, CEO João Andrade will provide investors with an update on the Group’s recent milestone developments and outline future growth plans. This will be followed by a Q&A session and refreshments. For security reasons, investors are required to bring identification to the event, as this is needed to enter the building.

To register for this event, please RSVP to ‘shareholderenquiries@stbridespartners.co.uk’ with ‘WideCells Investor Event’ in the subject line.

The Company is also pleased to announce that its Chief Financial Officer (‘CFO’) David Bridgland, who has previously been employed on a part-time basis, is now working with the Company full-time, effective 1 July 2017. With revenues now being generated from two of the Group’s divisions – namely WideCells division, which is focussed on stem cell storage and research, and CellPlan Limited, which has recently launched in the UK its core stem cell insurance product CellPlan – Mr Bridgland’s full-time appointment reflects WideCells Group’s increased operational presence. Mr. Bridgland will be attending the upcoming Investor Evening and will be available for questions.

WideCells Group CEO, João Andrade, said “We are delighted that David will now be working with us on a full-time basis. As CFO David has already proven invaluable in helping us build our Company into the revenue generative provider of stem cell services it is today and his move to a full-time position reflects our increased levels of activity and growing number of revenue streams. I look forward to his greater involvement in the Company as we continue to rapidly grow our innovative business. This is undoubtedly an exciting time for our Company and both David and myself look forward to meeting shareholders at our upcoming investor event on Wednesday 12 July 2017 as we provide an overview of recent corporate developments and outline our exciting plans for the future.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    WideCells Group PLC

    More articles like this

    WideCells Group PLC

    Umbilical blood injects new life into 8-month-old baby

    An 8-month-old girl who had severe combined immune deficiency (SCID) underwent a successful hematopoietic stem cell transplant surgery in Shanghai. The stem cell was taken from umbilical cord blood. Widecells Group PLC (LON:WDC) are leading a

    WideCells Group PLC

    Leukaemia: A Guide To The Cancer Of The Blood

    It is not hereditary, and it is not contagious. It is, however, one of the diseases that kills more children than many others. The word ‘leukaemia’ refers to a group of cancers that spread through the

    WideCells Group PLC

    Autism Treated With Stem Cells

    Researchers at Duke University have utilized autologous (the patient’s own) stem cell infusions to promote increased connectivity in the brain that allowed for improved communication and language abilities in children with Autism Spectrum Disorder (ASD). The

    WideCells Group PLC

    Cord blood banking industry expected to grow

    The list of decisions for new parents already seems endless but it continues to grow as new advances in medicine and technology open new doors for healthcare. Many private companies offer services for collecting and storing